Literature DB >> 26209505

NICE guidance on nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer.

Caroline J Hall1, Nicola Hay2, Elisabeth George2, Amanda I Adler2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26209505     DOI： 10.1016/S1470-2045(15)00189-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis.

Authors:  Biao Gu; WenChuang Gao; HongJun Chu; Jian Gao; Zhi Fu; Hui Ding; JunJie Lv; QingQuan Wu
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

2.  Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals.

Authors:  Liz Morrell; Sarah Wordsworth; Anna Schuh; Mark R Middleton; Sian Rees; Richard W Barker
Journal:  BMC Health Serv Res       Date:  2018-05-31       Impact factor: 2.655

3.  An open-label feasibility study of nintedanib combined with docetaxel in Japanese patients with locally advanced or metastatic lung adenocarcinoma after failure of first-line chemotherapy.

Authors:  Noboru Yamamoto; Hirotsugu Kenmotsu; Koichi Goto; Koji Takeda; Terufumi Kato; Masayuki Takeda; Hidehito Horinouchi; Isao Saito; Akiko Sarashina; Tetsuya Tanaka; Nassim Morsli; Kazuhiko Nakagawa
Journal:  Cancer Chemother Pharmacol       Date:  2018-08-03       Impact factor: 3.333
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.